These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 1426293)
1. Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. Salvadori B; Rovini D; Squicciarini P; Conti R; Cusumano F; Grassi M Eur J Surg Oncol; 1992 Oct; 18(5):438-41. PubMed ID: 1426293 [TBL] [Abstract][Full Text] [Related]
2. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L; J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260 [TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of resectable breast cancer: a report of 6 263 cases]. Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535 [TBL] [Abstract][Full Text] [Related]
4. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Bijker N; Rutgers EJ; Peterse JL; van Dongen JA; Hart AA; Borger JH; Kroon BB Cancer; 1999 Apr; 85(8):1773-81. PubMed ID: 10223572 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of subcutaneous mastectomy with radical mastectomy. Horiguchi J; Iino JHY ; Takei H; Koibuchi Y; Iijima K; Ikeda F; Ochiai R; Uchida K; Yoshida M; Yokoe T; Morishita Y Anticancer Res; 2001; 21(4B):2963-7. PubMed ID: 11712794 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
7. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007 [TBL] [Abstract][Full Text] [Related]
8. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA Breast J; 2006; 12(2):159-64. PubMed ID: 16509842 [TBL] [Abstract][Full Text] [Related]
9. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients. Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence. Metz JM; Schultz DJ; Fox K; Glick J; Solin LJ Cancer J Sci Am; 1999; 5(2):77-83. PubMed ID: 10198729 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A; J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592 [TBL] [Abstract][Full Text] [Related]
12. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Strom EA; Woodward WA; Katz A; Buchholz TA; Perkins GH; Jhingran A; Theriault R; Singletary E; Sahin A; McNeese MD Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1508-13. PubMed ID: 16169678 [TBL] [Abstract][Full Text] [Related]
13. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981 [TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
16. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
18. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040 [TBL] [Abstract][Full Text] [Related]
19. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
20. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]